Quarterly report · Q2
8129.TEDINET S100PLCG
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥679.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥1.27T | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥620.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥4.1bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥1.9bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥7.4bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥18.2bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.8bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥6.0bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥5.1bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥3.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.4bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.3bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥3.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥3.3bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥740.6bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥702.4bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥695.9bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥495.0bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥461.1bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥245.6bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥241.3bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥240.7bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥102.1bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥94.3bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥97.9bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥90.0bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥97.1bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥88.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥10.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥16.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥11.6bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥407m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥11.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.4bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥3.0bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥4.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.2bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥51.01 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.79 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥189.7 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.39 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.84 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥46.88 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥174.48 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥42.62 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 33.1% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.3% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.5% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥28.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥28.3bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥850m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥45.1bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥45.1bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥878m |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.8bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3.7bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥478m |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥654.8bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥631.0bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥23.8bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥3.3bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥3.3bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.5bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥782m |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥246m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥708.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥679.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥28.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥4.9bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥28.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥28.3bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥996m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥45.5bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥45.4bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥5m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥4.0bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥819m |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥3.2bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥312m |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥597.0bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥572.6bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥24.4bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥667m |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥100m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥649.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥620.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥28.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥2.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 580
| Item | Context | Value | Unit |
|---|---|---|---|
| Net sales | CurrentYTDDuration | 679719000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E02608-000MedicalProductsRetailReportableSegmentsMember | 3331000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E02608-000DispensingPharmacyReportableSegmentsMember | 878000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember | 478000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E02608-000OtherRelatedBusinessReportableSegmentMember | 246000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 4934000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -850000000 | JPY |
| Operating income | CurrentYTDDuration | 4084000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2022-11-14 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第75期第２四半期(自 2022年７月１日 至 2022年９月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)東邦ホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | TOHO HOLDINGS CO.,LTD. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役ＣＥＯ 有働 敦 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都世田谷区代沢五丁目２番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | ０３（３４１９）７８９３ | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)管理本部長 兼 財務部長 水澤 義昭 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都世田谷区代沢五丁目２番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | ０３（３４１９）７８９３ | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)管理本部長 兼 財務部長 水澤 義昭 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E02608 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 81290 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)東邦ホールディングス株式会社 | |
| Filer name in english | FilingDateInstant | TOHO HOLDINGS CO.,LTD. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2022-04-01 | |
| Current period end date | FilingDateInstant | 2022-09-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2023-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2021-04-01 | |
| Comparative period end date | FilingDateInstant | 2021-09-30 | |
| Previous fiscal year end date | FilingDateInstant | 2022-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |